328 related articles for article (PubMed ID: 18395381)
21. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine.
Singh KK; Vingkar SK
Int J Pharm; 2008 Jan; 347(1-2):136-43. PubMed ID: 17709216
[TBL] [Abstract][Full Text] [Related]
22. Consideration of ethics in primaquine therapy against malaria transmission.
Baird JK; Surjadjaja C
Trends Parasitol; 2011 Jan; 27(1):11-6. PubMed ID: 20846906
[TBL] [Abstract][Full Text] [Related]
23. [Manifestation of glucose-6-phosphate dehydrogenase deficiency caused by primaquine in malaria therapy].
Blümel P; Stögmann W
Padiatr Padol; 1983; 18(3):313-7. PubMed ID: 6350992
[TBL] [Abstract][Full Text] [Related]
24. [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
Telgt DS; Mulder L; Dolmans WM
Ned Tijdschr Geneeskd; 1997 Sep; 141(37):1783-6. PubMed ID: 9545728
[TBL] [Abstract][Full Text] [Related]
25. Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
Dua VK; Sharma VP
Ann Trop Med Parasitol; 2001 Oct; 95(7):655-9. PubMed ID: 11784418
[TBL] [Abstract][Full Text] [Related]
26. Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
Dao NV; Cuong BT; Ngoa ND; Thuy le TT; The ND; Duy DN; Dai B; Thanh NX; Chavchich M; Rieckmann KH; Edstein MD
Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):534-9. PubMed ID: 17368694
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary edema due to Plasmodium vivax malaria in an American missionary.
Illamperuma C; Allen BL
Infection; 2007 Oct; 35(5):374-6. PubMed ID: 17721740
[TBL] [Abstract][Full Text] [Related]
28. Failure of primaquine therapy for the treatment of Plasmodium ovale malaria.
Bottieau E; Van Gompel A; Peetermans WE
Clin Infect Dis; 2005 Nov; 41(10):1544-5. PubMed ID: 16231275
[No Abstract] [Full Text] [Related]
29. [Clinical importance of hemolysis in the prophylactic treatment of malaria using primaquine on persons with a glucose-6-phosphate dehydrogenase deficit].
Bronshteĭn AM; Ozeretskovskaia NN; Benediktov II; Ibragimov GI; Dzhafarova SKh
Med Parazitol (Mosk); 1975; 44(3):282-8. PubMed ID: 1177819
[No Abstract] [Full Text] [Related]
30. Reinventing primaquine for endemic malaria.
Baird JK
Expert Opin Emerg Drugs; 2012 Dec; 17(4):439-44. PubMed ID: 22998791
[TBL] [Abstract][Full Text] [Related]
31. Primaquine induced hemolysis in a Thai soldier.
Karwacki JJ; Shanks GD; Kummalue T; Watanasook C
Southeast Asian J Trop Med Public Health; 1989 Dec; 20(4):555-6. PubMed ID: 2639511
[No Abstract] [Full Text] [Related]
32. Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis.
Bryan JP
Am J Trop Med Hyg; 2006 Sep; 75(3):416-20. PubMed ID: 16968914
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Elmes NJ; Nasveld PE; Kitchener SJ; Kocisko DA; Edstein MD
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1095-101. PubMed ID: 18541280
[TBL] [Abstract][Full Text] [Related]
34. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug.
Clyde DF
Bull World Health Organ; 1981; 59(3):391-5. PubMed ID: 6976846
[TBL] [Abstract][Full Text] [Related]
35. Acute respiratory distress syndrome in a case of Plasmodium ovale malaria.
Rojo-Marcos G; Cuadros-González J; Mesa-Latorre JM; Culebras-López AM; de Pablo-Sánchez R
Am J Trop Med Hyg; 2008 Sep; 79(3):391-3. PubMed ID: 18784231
[TBL] [Abstract][Full Text] [Related]
36. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.
Buchachart K; Krudsood S; Singhasivanon P; Treeprasertsuk S; Phophak N; Srivilairit S; Chalermrut K; Rattanapong Y; Supeeranuntha L; Wilairatana P; Brittenham G; Looareesuwan S
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):720-6. PubMed ID: 12041544
[TBL] [Abstract][Full Text] [Related]
37. [Clinical experience of primaquine use for treatment of vivax and ovale malaria in Japanese travelers].
Kobayashi T; Kato Y; Yamauchi Y; Ujiie M; Takeshita N; Mizuno Y; Kanagawa S; Kano S; Ohmagari N
Kansenshogaku Zasshi; 2013 Jan; 87(1):22-6. PubMed ID: 23484374
[TBL] [Abstract][Full Text] [Related]
38. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine.
Clyde DF; McCarthy VC
Am J Trop Med Hyg; 1977 May; 26(3):562-3. PubMed ID: 326072
[TBL] [Abstract][Full Text] [Related]
39. Primaquine: the risks and the benefits.
Ashley EA; Recht J; White NJ
Malar J; 2014 Nov; 13():418. PubMed ID: 25363455
[TBL] [Abstract][Full Text] [Related]
40. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
Carmona-Fonseca J; Maestre A
Acta Trop; 2009 Nov; 112(2):188-92. PubMed ID: 19653988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
